Loading...
Strategic & Capital Advisory 2018-10-04T17:52:59+00:00

WHAT WE OFFER

CAPITAL ADVISORY

Growing companies can use capital throughout their trajectory to accelerate development. This capital can come in a variety of forms, depending on a company’s needs, stage of development and operating profile. ASGARD can help a company determine what form of capital is best suited for its plans and maneuver around structuring constraints.

Types of Scenarios and Forms of Capital
STRATEGIC ADVISORY

ASGARD offers its clients advice on how best to deploy capital as well as support companies with outsourced corporate development and mergers and acquisitions expertise. We also assist companies and their boards with strategic planning initiatives.

WHERE WE SOURCE CAPITAL

ASGARD has deep relationships with a broad network of capital providers from which it can select and negotiate the best possible financing proposal. These sources include:

  • ASGARD funds
  • Commercial banks
  • Family offices
  • Hedge funds
  • High net worth individuals
  • Private equity funds
  • Strategic investors
  • Venture capital funds

 

WHY ASGARD

ASGARD differentiates itself by its approach, its expertise and its alignment with clients. We can improve the terms of a transaction, shorten the time to success and minimize management distraction.

We pride ourselves at being able to think multi-disciplinarily rather than being constrained by traditional silos. We have operated companies and been clients ourselves. As a result, we collaborate with clients instead of talking at them and pushing them into transactions that don’t make sense. We have been principal investors and know how shareholders and lenders determine their investment criteria and view their investments. We have also worked on Wall Street and bring top-tier bank practices to our clients. Bringing all this under one roof sets us apart from other firms.

Collectively, the partners at ASGARD have arranged and advised on more than $100 billion in transactions and have significant expertise. We bring this multi-functional expertise to our clients and enable them to navigate their capital and growth decisions effectively. We also help negotiate directly with banks and investors on behalf of our clients.

We ensure we are aligned with our clients in objective and philosophy. Because we are truly independent, we are not beholden to funds to direct business to us or banks for deal flow. ASGARD does not take on every client and primarily provides its advisory services to our portfolio companies. We do partner with select non-portfolio companies where we believe we can be a meaningful driver for the company’s success. For your success.

ADVISORY EXPERIENCE

Historical transactions correspond to our partners’ experience at prior institutions.

EQUITY
$84 million
2007
Achaogen
EQUITY
$101 million
2016
Affymax, Inc.
EQUITY
$86 million
2009
Amarin Corporation
EQUITY
$70 million
2009
Anadys Pharma.
EQUITY
$18 million
2009
Anaptys Bio
EQUITY
$86 million
2017
ARINC
LBO FINANCING
$600 million
2008
Armored Auto Group
LBO FINANCING
$300 million
2011
Auspex Pharma.
EQUITY
$70 million
2014
Auspex Pharma
EQUITY
$97 million
2014
Auspex Pharma.
EQUITY
$260 million
2015
Biota Pharma
ADVISORY
$47 million
2015
Biotie Therapies
DEBT
€ 33 million
2015
Biotie Therapies
EQUITY
$64 million
2015
B/E Aerospace
DEBT
$600 million
2008
B/E Aerospace
DEBT
$475 million
2008
B/E Aerospace
DEBT
$650 million
2010
Celladon
EQUITY
$51 million
2014
Celladon
EQUITY
$44 million
2014
Centene Corporation
DEBT
$1,200 million
2016
Clearside Biomedical
EQUITY
$50 million
2016
Clearside Biomedical
EQUITY
$36 million
2016
Cogent Comm.
DEBT
$200 million
2007
CoLucid Pharma.
EQUITY
$55 million
2015
CoLucid Pharma
EQUITY
$75 million
2016
Covad Communications
ADVISORY
$304 million
2007
Delta Air Lines
EXIT FINANCING
$2,500 million
2007
Exar Corporation
EQUITY
$120 million
2005
Exelixis, Inc.
EQUITY
$155 million
2015
Fabrinet, Inc.
EQUITY
$98 million
2010
Freedom Group
DEBT
$200 million
2009
Genelabs Technologies
ADVISORY
$57 million
2008
Genocea Biosciences
EQUITY
$66 million
2014
Genocea Biosciences
EQUITY
$50 million
2015
Huish
DEBT
$875 million
2007
Huish
DEBT
$625 million
2008
Ingles
DEBT
$575 million
2009
Intrexon Corporation
EQUITY
$230 million
2015
Invuity, Inc.
EQUITY
$48 million
2015
Jazz Semiconductor
ADVISORY
$260 million
2006
Kenexa
EQUITY
$70 million
2005
JBS
DEBT
$700 million
2009
JBS
DEBT
$400 million
2011
JBS
DEBT
$650 million
2011
Limited Brands
DEBT
$500 million
2009
Limited Brands
DEBT
$1,000 million
2012
Loxo Oncology
EQUITY
$80 million
2014
Loxo Oncology
EQUITY
$41 million
2016
Loxo Oncology
EQUITY
$138 million
2017
MacGray
DEBT
$150 million
2005
Macy's
DEBT
$1,500 million
2010
Medtech SA
EQUITY
$15 million
2015
Medtech SA
ADVISORY
$167 million
2016
Novamed Pharma.
ADVISORY
$105 million
2011
PeopleSupport
EQUITY
$96 million
2006
Polycom
ADVISORY
$220 million
2007
Qiao Xing Mobile
EQUITY
$160 million
2007
Rackspace
EQUITY
$188 million
2008
Recovery Centers of America
DEBT
$230 million
2015
RedHill Biopharma
EQUITY
$9 million
2014
Santarus
ADVISORY
$2,600 million
2013
Supervalu
DEBT
$1,000 million
2009
Surgery Partners
DEBT
$400 million
2016
Tabula Rasa
EQUITY
$59 million
2016
Toys R Us
DEBT
$1,675 million
2010
Tracon Pharma
EQUITY
$41 million
2015
Tracon Pharma
EQUITY
$25 million
2016
Tracon Pharma
EQUITY
$15 million
2016
Tokai Pharma.
EQUITY
$97 million
2014
TVN Entertainment
ADVISORY
Undisclosed
2009
Tyson Foods
DEBT
$810 million
2009
United Air Lines
DEBT
$2,100 million
2007
Victory Pharma.
EQUITY
$45 million
2009
Victory Pharma.
ADVISORY
$170 million
2009
Wendy's
DEBT
$565 million
2009
Wyle
DEBT
$175 million
2010
XO Communications
DEBT
$75 million
2008
XO Holdings
DEBT
$780 million
2008

CONTACT US

Find out how our experience can make a real difference for you.

CONTACT US